½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 22 May 2020 ¨C 20:00 (CEST) ¨C regulated information

Acquisitions of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, ½ðºÌÓéÀÖ³Ç SA/NV (¡°½ðºÌÓéÀֳǡ± or the ¡°Company) (Euronext Brussels: ½ðºÌÓéÀÖ³Ç) hereby discloses certain information in relation to its Share Repurchase Program 2020. 

Under this program, ½ðºÌÓéÀÖ³Ç has requested a financial intermediary to repurchase up to 1.2 million ½ðºÌÓéÀÖ³Ç shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 15 June 2020, effective as from 25 March 2020, to cover current and future obligations under ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans for its personnel. The validity of this agreement has now been extended from 15 June 2020 to 29 July 2020.In the framework of this Share Repurchase Program 2020, ½ðºÌÓéÀÖ³Ç repurchased 86 041 ½ðºÌÓéÀÖ³Ç shares on Euronext Brussels in the period from 13 May 2020 up to and including 22 May 2020, as follows: 

Also in connection with the management of ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans, on 22 May 2020, ½ðºÌÓéÀÖ³Ç has acquired and ½ðºÌÓéÀÖ³Ç Fipar SA/NV (an indirect subsidiary of ½ðºÌÓéÀÖ³Ç) has simultaneously sold, in a related party transaction, 4 101 306 ½ðºÌÓéÀÖ³Ç shares at € 81.76 per share, through the central orderbook of Euronext Brussels. 

Disposals of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, ½ðºÌÓéÀÖ³Ç announces that, following exercises of stock options by members of its personnel, it has disposed of ½ðºÌÓéÀÖ³Ç shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group, as follows:

On 22 May 2020, taking into account the acquisitions of own shares mentioned in the first section and after settlement of the deliveries of shares to members of the personnel mentioned in this section, ½ðºÌÓéÀÖ³Ç owned 5 290 281 ½ðºÌÓéÀÖ³Ç shares, which represent 2.72% of the total number of shares issued by the company (194 505 658).

An updated overview of the ½ðºÌÓéÀÖ³Ç large shareholdings is available on ½ðºÌÓéÀֳǡ¯s website via the following .

This press release is available on ½ðºÌÓéÀֳǡ¯s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, ½ðºÌÓéÀÖ³Ç
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, ½ðºÌÓéÀÖ³Ç
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news